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As the utility of liver-specific magnetic resonance imaging
(MRI) increases, it is pertinent to optimize and expand
protocols to improve accuracy and foster evolution of
techniques; in turn, positive impacts should be seen in
patient management. This article reports on the latest
expert thinking and current evidence in the field of liver-
specific MRI, as discussed at the 6th International Forum
for Liver MRI, which was held in Vancouver, Canada in
September 2012. Topics discussed at this forum
described the use of gadoxetic acid-enhanced MRI for the
assessment of liver function at the segmental level; to
increase accuracy in the diagnosis of liver metastases; to
overcome current challenges in patients with cirrhosis,
including management of arterial hypo-/isovascular, hep-
atobiliary phase hypointense nodules; and the data which
would be required in order to recommend the use of this
modality in hepatocellular carcinoma management
guidelines. Growing evidence suggests that gadoxetic
acid-enhanced MRI can help to improve the management
of patients with a number of different liver disorders;
however, more data are needed in some areas, and there
may be a case for developing an interpretation guideline
for gadoxetic acid-enhanced MRI findings to aid
standardization.
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THE UTILITY AND application of liver-specific MRI is
expanding rapidly, creating new challenges and
opportunities. Optimization of existing protocols and
further technological developments to meet the grow-
ing demand in this field will improve the accuracy of,
and increase the indications for, liver-specific MRI. In
time, evolution of strategies for MRI with liver-specific
contrast agents should positively impact patient man-
agement strategies in routine clinical practice.
Current challenges in liver-specific MRI, alongside the
latest evidence in this field, were discussed at the 6th
International Forum for Liver MRI, held in Vancouver,
Canada, in September 2012, and attended by approxi-
mately 100 international abdominal radiologists, hepa-
tologists, pathologists, and surgeons. The authors of this
manuscript presented to the entire forum recent data in
four key areas; these topics were then discussed further
in breakout workgroups, each consisting of approxi-
mately 25 expert participants. The areas of discussion
were: (i) Accurate assessment of liver function, (ii)
Remaining challenges in metastatic liver disease, (iii)
Remaining challenges in cirrhosis, and (iv) Hepatocellu-
lar carcinoma (HCC) management guidelines, the case
for inclusion of liver-specific imaging.
Each workgroup generated and refined several con-
sensus statements, with the aim to inform and advance
current thinking in the subject areas, based on
the experience and opinions of the expert participants.
The consensus statements were then presented to the
entire forum, refined according to further discussion,
and voted on using an electronic voting system; the
available options were “agree,” “disagree,” or “abstain.”
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This manuscript summarizes the consensus of the
forum attendees. The consensus statements are pre-
sented throughout the manuscript along with support-
ing evidence, and the number and percentage of liver
forum participants who agreed with each statement
are also reported. The authors’ intent is that some con-
sensus statements will be useful for radiologists in
their daily clinical routine, while others will help to
identify areas in which further research is needed.
It should be noted that this manuscript focuses on
liver-specific MRI with gadoxetic acid. The focus on
gadoxetic acid-enhanced MRI reflects the emphasis of
the Liver Forum, in which scientific data were pre-
sented only for MRI performed with this agent. It is,
therefore, beyond the scope of the current manuscript
to provide comparisons of gadoxetic acid and other
contrast agents used in liver-specific MRI. Some of
the consensus statements may also apply to other
liver-specific contrast agents.
1. ACCURATE ASSESSMENT OF LIVER FUNCTION
Postoperative mortality following liver resection has
been decreasing over the last two decades, with many
centers reporting mortality rates <1% (1,2). Currently,
the largest cause of postoperative mortality after liver
resection is liver failure, and to avoid these fatalities,
an accurate assessment of the future liver remnant
(FLR) should be part of the preoperative work-up. The
FLR must be of sufficient volume and quality to sus-
tain postoperative liver function and enable
regeneration.
In patients with normal liver function, the FLR is
assessed in terms of volume measurements only,
commonly using computed tomography (CT) or MRI
(3). In patients with healthy liver parenchyma, a FLR
>20% of the total estimated functional liver volume is
usually sufficient. However, worldwide opinions on
the minimum required FLR volume vary in the range
of 15% to 40% (4).
Many patients being considered for resection do not
have normal liver parenchyma. This problem is com-
mon in patients with HCC, with the majority of these
tumors occurring in patients with cirrhosis and com-
promised liver function. As chemotherapy is used
more frequently in multimodality treatment plans for
patients with colorectal cancer liver metastases
(CRCLM), chemotherapy-associated parenchymal dys-
function is increasingly encountered in this patient
group (5), and has shown an association with
increased morbidity, and in some cases even mortal-
ity, after resection. In patients with decreased liver
function, the minimum volume of the FLR has to be
increased according to the level of parenchymal dam-
age and associated liver dysfunction (6).
Currently, evaluations of liver function fall into
three main categories: routine laboratory tests meas-
uring surrogate markers (serum bilirubin, albumin,
coagulation factors, etc); scoring systems combining
laboratory and clinical information (eg, Child-
Turcotte-Pugh and Model for end-stage liver disease
[MELD] scores); and quantitative liver function tests
(eg, indocyanine green [ICG] clearance, albumin syn-
thesis tests, LiMAx), which measure specific aspects
of function (eg, microsomal or cytosol function, or
hepatic membrane receptor expression) or hepatic
perfusion (clearance of high extractable substances
such as ICG, sorbitol, or galactose) (7,8). However, the
use of liver function tests for preoperative assessment
of patients varies worldwide (4), and regional algo-
rithms for HCC treatment strategies include different
combinations of liver function assessment methods,
with nonuniform adoption of guideline recommenda-
tions being common. For example, the European
Association for the Study of the Liver - European
Organisation for Research and Treatment of Cancer
(EASL-EORTC) and Barcelona Clinic Liver Cancer
(BCLC) practice guidelines endorse Child-Turcotte-
Pugh score, portal pressure, and bilirubin for patient
staging (9), whereas guidelines from the Japan Society
of Hepatology (JSH) suggest the use of the Child-
Turcotte-Pugh score alone (10). Furthermore, local
practices in many Asian centers include ascites, bili-
rubin and ICG measurements (11).
Current methods for assessing liver function, as
outlined above, measure global function, with no
consideration for segmental variations in function or
dysfunction (ie, any reduction in liver function is
assumed to be uniform throughout the parenchyma).
However, in some conditions, liver function is not
homogeneously distributed, with large segmental var-
iations observed (12). Although postoperative mortal-
ity for patients undergoing liver resection is already
low, global functional assessment methods may result
in overly conservative decision-making, incorrectly
denying some patients potentially curative surgical
treatment. For example, if malignant lesions are
located preferentially in areas of the liver with dimin-
ished function, while areas free of malignant lesions
have more normal function, a larger amount of
hepatic parenchyma may be resected safely than
would be predicted based on global function tests.
Thus, there is a need to develop more sophisticated
methods to assess liver function at the segmental
level.
Imaging-Based Methods for Liver Function
Assessment
Imaging-based functional liver analyses have the
potential to provide more accurate, multicompartmen-
tal measurements, including data on a multitude of
liver function and physiology parameters within a sin-
gle examination. Additionally, the ability to perform
analyses on a segmental, or even subsegmental, level
would allow clinicians to detect and account for any
inhomogeneities in parenchymal function.
Hepatobiliary scintigraphic methods using radio-
pharmaceutical agents (technetium-99 nuclear iso-
tope [99mTc]-labeled iminodiacetic acid, galactosyl
serum albumin, or mebrofenin) have shown good cor-
relation with ICG clearance, but are hampered by
poor anatomical resolution (Fig. 1a) (13). To enable
accurate segmental assessment, a tomographic
method (single photon emission computed tomogra-
phy [SPECT]) should be used, rather than a planar
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imaging protocol (14). MRI is a multi-parametric tech-
nique that, apart from its use as diagnostic modality
for detection and characterization of focal liver lesions
and diffuse liver diseases, offers excellent anatomic
resolution, useful for treatment planning and volume-
try. In addition, physio-pathological information can
be obtained by including MRI sequences, which ena-
ble elastography, relaxometry, diffusion-weighted
imaging (DWI), and hepatobiliary phase (HBP) imag-
ing, generating functional data regarding parenchy-
mal architecture, fibrosis development, and hepatic
dysfunction (15–17).
Gadoxetic acid is taken up by functioning hepato-
cytes using uptake and excretion receptor pathways
common to other functional analysis agents (ICG,
99mTc-mebrofenin), namely, uptake by means of
organic anion-transporting polypeptide (OATP) 1B1/
B3 and excretion through multi-drug resistance-asso-
ciated protein 2 (MRP2) (18). Currently, an active area
of investigation is the potential use of gadoxetic acid-
enhanced MRI to evaluate hepatic function, and sev-
eral approaches have been explored (19–24).
The simplest approach is to perform static measure-
ments of parenchymal enhancement during the HBP
(20 min after injection of gadoxetic acid). Mean rela-
tive enhancement of the parenchyma has been shown
to correlate with the severity of cirrhosis (23) and
stage of fibrosis (22), liver function (as assessed by
surrogate marker measurements), and the risk of
postoperative liver failure (19). The relative uptake of
gadoxetic acid (signal intensity per liver volume) has
also been shown to correlate with ICG clearance (24).
The advantage of these static measurements is that
they are simple to perform, without the necessity of
additional sequences. However, the relationship
between signal intensity and gadoxetic acid concen-
tration is not linear, signal intensity can be con-
founded by several technical factors, and sampling
error can occur according to region-of-interest (ROI)
placement. A less subjective method that involves
measurement of the absolute change in T1 or T2*
relaxation with gadoxetic acid uptake has been shown
to correlate with the Child-Turcotte-Pugh score
(20,21). This technique, however, involves additional
scan sequences and dedicated software programs.
Hepatic uptake of gadoxetic acid occurs progres-
sively over time, and a single time point measurement
may be insufficient to reflect the enhancement profile
or the hepatic perfusion. To address this, a more com-
prehensive approach involving dynamic hepatic
gadoxetic acid-enhanced MRI has been investigated
as a functional analysis tool. In this approach, multi-
ple phases are acquired postinjection, and the paren-
chymal enhancement response over time in relation to
a single vascular input, for example the portal vein, is
plotted. A free deconvolution model then allows calcu-
lation of quantitative functional parameters, including
the hepatic extraction fraction (HEF; amount of con-
trast agent that would be eliminated in one passage
through the liver) and input relative blood flow (irBF;
a measure of perfusion) (25), which can be depicted
on high-resolution image maps (Fig. 1b). These
dynamic measures of hepatic function, which can be
assessed on segmental and subsegmental levels, are
significantly reduced in disease, even in mild cirrhosis
(26). Further refinement of this technique using a
dual-input, dual-compartment model can improve
combined functional and perfusion assessment, to
better evaluate focal liver lesions and diffuse hepatic
abnormalities (27). However, in their current form
these dynamic acquisitions are time consuming and
require dedicated software to complete the complex
modeling, limiting their usefulness in clinical practice.
Dynamic hepatic gadoxetic acid-enhanced MRI as a
method for assessment of liver function requires fur-
ther development and validation to explore its potential
and possible role in routine practice. However, because
there is no “gold standard” against which to compare
it, this is a problematic feat. In studies of this method
as a decision-making tool regarding liver function
assessment for patients considered for liver resection,
survival should ideally be the primary endpoint.
Figure 1. Imaging-based functional analyses of the liver: (a) hepatobiliary scintigraphy and (b) gadoxetic acid-enhanced MRI.
a: Hepatobiliary CT scintigraphy with a radiopharmaceutical tracer provides a low resolution map of liver function, allowing
lobular analysis (colored gating) (13). b: Hepatic extraction fraction MRI mapping of gadoxetic acid clearance provides high
resolution anatomical images which can be interpreted at a segmental level. Part (a) reproduced with kind permission from
Springer ScienceþBusiness Media: J Gastrointest Surg, Assessment of future remnant liver function using hepatobiliary
scintigraphy in patients undergoing major liver resection, 2010;14:369–378, de Graaf W, et al, Part (b) reproduced with per-
mission from Magnetic resonance imaging for the assessment of liver function, published by Karolinska Institutet. Henrik
Nilsson, 2011, ISBN 978-91-7457-360-2.
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However, the number of patients needed to determine
a significant survival-related outcome benefit in a
randomized controlled trial would be prohibitively
large, given the low mortality rates currently observed
with hepatic resection (in one power analysis, it was
estimated that 15,614 patients would be required to
show a 33% relative reduction in operative mortality
(28). Furthermore, the relatively high cost of gadoxetic
acid-enhanced MRI dictates that no compromise in
diagnostic quality should be made to obtain functional
data. Dynamic, HBP, and functional sequences should
be optimized to make “one-stop-shop” MRI assessment
as accurate and cost-effective as possible. It is
expected that recent technological developments in MR
hardware, rapid sequences, and reconstruction techni-
ques (such as compressed sensing) will make high spa-
tial and temporal resolution T1-weighted imaging
possible for “one-stop-shop” MRI anatomic and func-
tional assessment of the liver. Confident extension of
indications for surgery using functional MRI assess-
ment, with maintenance of the current low mortality
rates, should be the goal for the future.
Consensus statement 1.1: Given the limitations of
current clinical parameters, there is a growing need to
develop accurate and reproducible quantitative tools
for regional liver function in patients being evaluated
for liver resection. These tools have the potential to
improve surgical decision-making and extend the
indications for curative intended treatment (77/85
[90.6%] agreement).
Consensus statement 1.2: Currently there is non-
uniformity in the method used for liver function eval-
uation in patients who are surgical candidates.
Comprehensive morphological and functional analysis
of the liver using hepatocyte-specific contrast-
enhanced MRI shows potential that warrants further
technical development and prospective clinical valida-
tion (79/84 [94.0%] agreement).
2. REMAINING CHALLENGES IN METASTATIC
LIVER DISEASE
The liver is a very common site of metastatic spread of
cancer, in addition to lymph nodes, lungs, and bone;
moreover, 30% to 70% of all cancer patients who die
from their disease have liver metastasis (29). The
most frequent primary cancers leading to liver metas-
tasis are those of the colon (50%), stomach, esopha-
gus, pancreas, breast, lung, and eye (29).
Imaging Features of Liver Metastases
Metastatic lesion appearance is influenced by tumor
growth and neo-arterial vascularity. Approximately
two thirds of metastases demonstrate arterial phase
hypoenhancement on dynamic imaging (hypovascular
metastases), with the remainder showing arterial
phase hyperenhancement (hypervascular metastases).
Hypervascular metastases occur more commonly from
primary pancreatic neuroendocrine or endocrine
tumors, renal cell carcinoma, or breast cancer (30).
Despite variable histologies and vascularity, metasta-
ses share common imaging features. Circumferential
arterial ring enhancement on dynamic contrast-
enhanced (CE) imaging is characteristic of metastases
(positive predictive value [PPV], 82%) (31); for hyper-
vascular metastases, the ring corresponds to the
enhancing edge of the tumor, while for hypovascular
metastases it corresponds to peritumoral desmoplas-
tic reaction, inflammatory cell infiltration, and vascu-
lar proliferation (32). High signal intensity is also
commonly seen on DWI (33), attributable to restricted
diffusion of water caused by hypercellularity (34). In
the delayed phase, hypervascular metastases can
show central hyperenhancement and peripheral hypo-
enhancement (30% cases); this “peripheral washout”
pattern is especially common in patients with neuro-
endocrine and carcinoid tumors (35). Metastases that
appear near isovascular to the liver parenchyma on
CE-MRI also occur, especially following chemotherapy
treatment.
Challenge of Current Imaging Modalities
CT and conventional MRI are the primary imaging
modalities used for the evaluation of suspected liver
metastases. A current challenge with metastatic dis-
ease is the characterization of subcentimeter, low-
density lesions on CT; these lesions are often benign,
but may be mucinous metastases, and a differential
diagnosis is important for patient outcome.
CT and MRI have a similar, acceptable sensitivity
for detection of metastases >1 cm (87–89%), but for
lesions <1 cm the sensitivity is much lower (60% for
MRI and 47% for CT) (36). This low sensitivity hin-
ders the selection of such patients for surgery and
suboptimal management may occur, whereby patients
with a large unrecognized metastatic burden may
undergo unnecessary surgery, or patients with poten-
tially resectable, yet undetected, metastases may
undergo incomplete resection. Intraoperative ultra-
sound (US) can aid detection of lesions missed at pre-
operative imaging; however, this modality is <100%
sensitive and cannot aid preoperative patient selection
or surgical planning. A technique that can accurately
and noninvasively characterize metastases <1 cm
could improve appropriate patient selection for sur-
gery and would aid the differential diagnosis of muci-
nous metastases.
Gadoxetic Acid-Enhanced MRI for Imaging
Metastases
For visualization of metastatic disease, liver-specific
MRI with gadoxetic acid has the advantage of a
pseudo–steady-state HBP, whereby hepatocytes pro-
gressively uptake contrast agent over many minutes
while metastases do not, providing a useful differen-
tial in relative enhancement (Fig. 2). In terms of imag-
ing, this means that metastases tend to appear
hypointense relative to the healthy parenchyma in the
HBP. Additionally, due to the high relaxivity of gadox-
etic acid, in the HBP (when the agent achieves a rela-
tively high intra-hepatocellular concentration) the
normal liver parenchyma enhances intensely,
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providing high parenchymal signal-to-noise ratio
(SNR) and high liver-to-lesion contrast-to-noise ratio
(CNR). Also, because the HBP persists as a pseudo–
steady-state for many minutes, there is a prolonged
window in which to acquire images, allowing high
resolution, near isotropic images to be acquired (with
multiple averages possible during free breathing using
navigator sequences), while maintaining high SNR
and CNR.
Added to dynamic phase images, HBP data can
improve the detection of metastases. In a study of 107
metastases in 46 patients, gadoxetic acid-enhanced
MRI including HBP images had a significantly higher
area under the receiver operating characteristic curve
and sensitivity compared with precontrast and post-
contrast dynamic phase images alone (0.91, 97.2%
versus 0.81, 79.9%, respectively; P < 0.05) (37). Sen-
sitivity was also higher in patients with small (1 cm)
metastases and a history of chemotherapy (91.6%
including HBP images, compared with 48.6% for pre-
contrast and dynamic postcontrast images only; P <
0.001) (37).
As a modality, gadoxetic acid-enhanced MRI has
demonstrated a higher sensitivity for focal liver lesion
detection (67–96%) than either nonenhanced MRI
(46–84%) or CT (61–85%) (38,39). Gadoxetic acid-
enhanced MRI was also more sensitive than tri-phasic
CE-spiral CT for the detection of subcentimeter
lesions (38.0–55.4% versus 26.1–47.3%) (38). For the
detection of metastatic disease, gadoxetic acid-
enhanced MRI has demonstrated higher sensitivity
than CE-multi-detector CT (MDCT); 96.4–97.3% ver-
sus 76.4–80.9%, respectively (40). Fifteen of 110
metastases were not detected using MDCT, but all of
these lesions were identified on gadoxetic acid-
enhanced MRI (40). Additionally, the three metastases
that could not be identified prospectively using either
imaging modality, could be seen retrospectively to
have subtle hypointensity in the HBP of gadoxetic
acid-enhanced MRI (40). It is important to note that
DWI was not performed in these studies. DWI is
known to improve the detection of metastatic disease
in the liver (41), and is complementary to gadoxetic
acid-enhanced MRI for the detection and characteriza-
tion of liver metastases (42); however, as discussed
further below, gadoxetic acid-enhanced MRI alone
may perform better than DWI alone (42).
Gadoxetic acid-enhanced MRI has also been shown
to be more specific than nonenhanced MRI and CT in
classification of benign versus malignant focal liver
lesions (98% versus 92% and 88%, respectively) (39)
and more accurate than MDCT in differentiating
metastases from cysts and hemangiomas (0.98 versus
0.89; P ¼ 0.0001) (40). This increased specificity was
associated with improved diagnostic confidence
(39,40). To our knowledge, no literature evidence has
compared dynamic extracellular contrast medium
(ECCM)-enhanced MRI with liver-specific MRI for the
evaluation of metastatic disease.
Although hypointensity in the HBP of gadoxetic
acid-enhanced MRI may improve the detection of met-
astatic disease, this finding in isolation is not specific
for metastases, being observed for several primary
neoplasms (eg, HCC, hepatocellular adenoma, cholan-
giocellular carcinoma [CCC]) and benign lesions (eg,
cysts and hemangiomas), as well as some pseudole-
sions (eg, focal parenchymal fat accumulation, perfu-
sion alterations, parenchymal changes associated
with chemotherapy, or locoablative therapy). Accurate
characterization of HBP hypointense lesions requires
assessment in the context of other available sequen-
ces, including T2-weighted images, DWI, and fat-
sensitive in- and opposed-phase images. DWI is well
established as a useful method for detecting meta-
static disease to the liver. Direct comparison of gadox-
etic acid-enhanced MRI versus DWI alone has shown
the superiority of gadoxetic acid-enhanced MRI for
liver metastasis detection (42); however, these meth-
ods are highly complementary and the combination of
DWI and gadoxetic acid-enhanced MRI shows great
promise for the detection and characterization of liver
metastases.
Consensus statement 2.1: The addition of hepato-
biliary phase imaging to routine sequences improves
the sensitivity for detection of metastatic disease to
the liver (59/60 [98.3%] agreement).
Consensus statement 2.2: Characterization of liver
lesions depicted with hepatobiliary phase imaging must
be performed in conjunction with routine sequences, to
improve accuracy (59/60 [98.3%] agreement).
Optimization of the Imaging Protocol
Because liver contrast enhancement (signal) is directly
related to contrast agent relaxivity (r1) and parenchy-






for any given contrast agent tissue concentration, sig-
nal can be maximized by optimizing the T1-weighting.
Figure 2. Schematic enhancement curves of a hypervascular
tumor (eg, metastasis or HCC) and the progressive uptake of
gadoxetic acid in the liver. Maximum enhancement in the
liver occurs at approximately 15–30 min and is present in a
pseudo–steady-state, permitting extended imaging times
during the hepatobiliary phase using navigator-based or
respiratory-triggered methods. This behavior of the delayed
phase facilitates acquisition of very high spatial resolution
images with high SNR/CNR performance.
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This can be achieved by selecting the optimal flip
angle (Fig. 3a). In gadoxetic acid-enhanced MRI, a flip
angle of 10 to 15 may be commonly applied for
dynamic sequences, but during the HBP where hepa-
tocyte concentration of gadoxetic acid is high, this is
unlikely to provide optimal signal and relative liver-to-
lesion enhancement (Fig. 3b). Nagle et al demon-
strated that for HBP imaging with gadoxetic acid, the
optimal flip angle was around 40, which provided
twice the liver-to-muscle contrast compared with a
15 flip angle (43). This increased relative enhance-
ment can translate into improved lesion detection: in
a comparison of low (10–12) and high (30–35) flip
angles for HBP imaging of focal liver lesions in gadox-
etic acid-enhanced MRI, the higher flip angle provided
a 74% increase in lesion-to-liver contrast, which was
associated with a higher detection rate for all lesions,
especially small ones (sensitivity 81% versus 66% for
low flip angle, P < 0.01), an increased conspicuity
score (especially for small lesions), and an increased
detection rate for HCC (97% versus 85%) (44). In this
study, conspicuity was increased for all types of
lesions, but this did not specifically include metasta-
ses; it is expected that this will hold true for meta-
static disease, although confirmatory studies are
needed.
Most of the current evidence for T1 signal optimiza-
tion in the HBP of liver-specific MRI is from healthy
volunteers. In patients with reduced parenchymal
function, hepatocyte uptake of gadoxetic acid and,
therefore, relative enhancement versus lesions would
be less. In patients with liver disease (eg, cirrhosis),
signal optimization by means of flip angle adjustment
may still be possible, but the optimal flip angle is
likely to be lower than 40, and further research is
required to determine the best sequence parameters.
Consensus statement 2.3: The optimization of T1-
weighting for hepatobiliary phase imaging results in
higher liver-to-lesion CNR and improves the conspicu-
ity and detection rate of liver lesions (59/64 [92.2%]
agreement).
3. REMAINING CHALLENGES IN CIRRHOSIS
Gadoxetic acid-enhanced MRI has several advantages
for noninvasive assessment of the cirrhotic liver,
including higher sensitivity for the diagnosis of HCC,
especially for lesions 2 cm (45–49); improved char-
acterization of arterially enhancing lesions without
definite “washout” (47,50); distinguishing arterially
enhancing pseudolesions from HCC (50,51); and
detection of lesions that are isointense to the paren-
chyma on all sequences apart from the HBP, and that
are at high risk of transforming to hypervascular HCC
(52,53). However, some limitations to the use of
gadoxetic acid-enhanced MRI in the cirrhotic liver
remain under discussion.
In some patients, particularly those with advanced
cirrhosis (Child-Turcotte-Pugh score B and C), gadox-
etic acid-enhanced MRI can show weak parenchymal
and venous enhancement (54,55), which may hamper
the detection of HCC and the assessment of portal
vein patency. A simple clinical measure to predict
reduced gadoxetic acid enhancement at MRI could
allow more appropriate selection of patients in whom
gadoxetic acid-enhanced MRI is likely to be beneficial
(versus those in whom an extracellular agent may be
more appropriate).
Studies investigating clinical markers of liver func-
tion as predictors of enhancement with gadoxetic acid
have shown variable findings. Routine clinical param-
eters such as aspartate aminotransferase (AST), total
bilirubin, albumin, and prothrombin activity have
shown correlations with gadoxetic acid enhancement
in some studies (56–60), although these were not
always predictive factors. Total bilirubin has been
used as a selection criterion in some centers, but the
cutoff value (between 2 and 3 mg/dL) is somewhat
arbitrary, and other causes of hyperbilirubinemia (eg,
Gilbert’s syndrome) exist which are not associated
with parenchymal dysfunction. ICG clearance has
shown variable degrees of association with gadoxetic
acid enhancement (58,61,62). MR elastography as a
Figure 3. Schematic of the relationship between signal intensity in liver-specific CE-MRI and T1-weighting (flip angle) at
increasing tissue concentrations of contrast agent (a), and schematic representation of relative signal intensity between
parenchyma in the HBP (high contrast agent concentration in hepatocytes) and a metastatic lesion (no uptake of contrast
agent) (b).
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measure of parenchymal stiffness was predictive in
one study (60), but elastography is not likely to be a
clinically feasible method for determining the suitabil-
ity of gadoxetic acid-enhanced MRI. A relatively con-
sistent association with reduced gadoxetic acid
uptake has been stage of cirrhosis, especially more
severe disease (Child-Turcotte-Pugh score C)
(23,59,61,63). MELD scoring may be a more objective
assessment of liver function than the older Child-
Turcotte-Pugh score, and it correlates with mortality.
Early reports also suggest a correlation between the
MELD score and intensity of delayed parenchymal
and biliary enhancement on gadoxetic acid-enhanced
MRI (64,65). In principle, the most reliable markers
for gadoxetic acid uptake should be hepatic expres-
sion of the transporters OATP 1B1/B3 and MRP2
(66,67). However, evaluation of this expression
involves immunohistochemical staining of biopsy or
surgical tissue, which would typically be unavailable,
as few centers perform routine immunohistological
analysis for these proteins. More research is needed
into the correlations between OATP 1B1/B3 and
MRP2 expression, gadoxetic acid uptake, and markers
of liver function, to translate the evidence into mean-
ingful clinical practice that can improve patient
management.
Consensus statement 3.1: Gadoxetic acid-enhanced
MRI in some patients with cirrhosis can show weak
lesion-to-liver contrast in all phases and poor venous
enhancement, which may hamper the diagnosis of
HCC and assessment of portal vein patency. Multicen-
ter studies to determine the correlation between
enhancement at gadoxetic acid-enhanced MRI and
markers of liver function are required (66/77 [85.7%]
agreement).
Infrequently, nodules that are isointense to the
parenchyma in the dynamic phases and hyperintense
in the HBP of gadoxetic acid-enhanced MRI are dis-
covered, and these nodules may also appear isoin-
tense on T2-weighted sequences. Limited data from
the literature suggest that the vast majority of such
lesions are benign, regenerative or hyperplastic nod-
ules (fed by the portal vein), or focal nodular hyper-
plasia (FNH)-like lesions (68). Progression to a
hypervascular nodule has been described rarely (<1%
cases) (69,70), although arterial hypovascularity may
signify a risk for malignancy (high-grade dysplastic
nodules [DNs] or early HCC).
Consensus statement 3.2: Nodules with arterial
hypo-/isovascularity, venous isovascularity and HBP
hyperintensity are likely to be benign; however, the
role of size in predicting the outcome of these nodules
is still not clear (56/75 [74.7%] agreement)
Hypo-/Isovascular, HBP Hypointense Nodules
Hypointensity in the HBP of gadoxetic acid-enhanced
MRI is suggestive of premalignancy or malignancy,
independently of vascular enhancement pattern;
indeed, almost all HCC and some high-grade DNs are
hypointense in this phase (71). Therefore, gadoxetic
acid-enhanced MRI has increased the detectability of
small hypo- or isovascular premalignant or early HCC
(“borderline”) lesions (47), which are common in cir-
rhotic patients. The detection of such nodules is
important, because studies have shown that vascular
invasion, metastatic spread, and recurrence after
radiofrequency ablation are less frequent in hypovas-
cular versus hypervascular small HCC (72,73). While
some low-grade DNs and regenerative nodules (RN)
also show hypointensity in the HBP (47,74), these
nodules are usually <1 cm (75), while high-grade DN
and early HCC tend to be >1 cm. Therefore, a hypo-
vascular or isovascular, HBP hypointense nodule of
>1 cm in at-risk patients would strongly suggest a
premalignant or malignant lesion.
The prognosis of hypovascular or isovascular
“borderline” nodules in cirrhotic patients has been
studied in several centers. Kumada et al reported that
13/49 (26.5%) of nodules developed arterial hypervas-
cularity during the follow-up period (3–15 months,
median 6 months), and these lesions showed a greater
change in size than nonvascularized lesions (53). Size
of nodule was found to be a significant factor for prog-
nosis, with a 1-year hypervascularization risk of 17%
for nodules <1.5 cm compared with 77% for those
1.5 cm (P ¼ 0.0147) (53). Another study by Motosugi
et al reported arterial vascularization in 16/135
(11.9%) nodules, with a median time to hypervascula-
rization of 288 days (median follow-up duration, 296
days) (76). Size was again related to hypervasculariza-
tion, with a 1-year risk of 37.6% for nodules >1 cm,
compared with 15.6% for all nodules. A receiver oper-
ating characteristic (ROC) analysis revealed an optimal
cutoff in nodule size to predict hypervascularization of
1.1 cm (76). Presence of fat (P < 0.01), enlargement
during follow-up (P ¼ 0.04) and T2 hyperintensity (P ¼
0.06) were also associated with an increased risk of
hypervascularization (76). Akai et al further demon-
strated a relationship between initial nodule size and
hazard ratio for HCC development, based on 17/130
(13.1%) nodules that developed hypervascularity (77).
The cumulative rate for development of classic HCC
was 3.2% at 1 year, and 11.1% and 15.9% after 2 and
3 years, respectively. Takayama et al performed a mul-
tivariate analysis which showed that a nodule size of
0.9 cm was a significant predictive factor for malig-
nant transformation (enlargement and/or vasculariza-
tion; P < 0.05) (78).
Therefore, while hypo-/isovascular, HBP hypointense
nodules smaller than 1 cm have some risk for malig-
nant transformation, the risk appears to be substan-
tially greater for larger nodules. The strong association
between nodule size and tumor transformation, and
the poorer prognosis following hypervascularization
(increased invasion, spread, and recurrence), suggests
that these “borderline” lesions may warrant expedited
follow-up, assessment using other imaging modalities
or biopsy and/or consideration for treatment; however,
the optimal management strategy is, as yet, unknown
and more research is needed.
Consensus statement 3.3: Cirrhosis-associated nod-
ules >1 cm with arterial hypo-/isovascularity and
HBP hypointensity may have a high risk of becoming
hypervascular HCC within 1 year (59/74 [79.7%]
agreement).
522 Sirlin et al.
Consensus statement 3.4: Features that suggest a
higher likelihood of developing hypervascular HCC
may include lesion size, lesion growth, T2 hyperinten-
sity, and intralesional fat. Further studies are needed
to confirm these and other potential predictors (64/72
[79.7%] agreement).
Consensus statement 3.5: Arterial hypovascular/
isovascular, HBP hypointense nodules >1 cm in diam-
eter can be considered for biopsy or additional/close-
interval imaging follow-up (60/65 [92.3%] agreement).
4. HCC MANAGEMENT GUIDELINES: THE CASE
FOR INCLUSION OF LIVER-SPECIFIC IMAGING
Currently, only one set of guidelines for the manage-
ment of HCC includes liver-specific MRI in its diag-
nostic algorithm: in its 2010 guidelines update the
JSH recommends gadoxetic acid-enhanced MRI to
further investigate nodules that have not shown a
clear arterial phase hyperenhancement and portal
venous or delayed phase “washout” pattern on a
dynamic imaging technique (CE-CT, -MRI, or -US)
(10).
Other recently updated guidelines from the EASL-
EORTC (9) and the American Association for the
Study of Liver Diseases (AASLD) (79) make no con-
trast agent recommendations. These guidelines both
suggest that suspected HCC <1 cm should receive
follow-up imaging with US, while nodules >1 cm
should be investigated by MDCT or dynamic CE-MRI
for the characteristic arterial phase hyperenhance-
ment and venous/delayed phase “washout” pattern. If
this pattern of contrast enhancement is not observed
using the initial dynamic imaging modality, the alter-
native modality or biopsy is recommended. If a second
modality is used and also equivocal, biopsy is recom-
mended. However, these guidelines make no sugges-
tion as to which modality should be the initial
imaging method.
In deciding on the initial imaging modality for fur-
ther investigation of suspected HCC, the accuracy of
MDCT, ECCM-MRI, and gadoxetic acid-enhanced MRI
for the diagnosis of HCC should be considered. To our
knowledge, there has been only one direct comparison
reported between gadoxetic acid-enhanced MRI and
ECCM-MRI for the detection of HCC, in which gadox-
etic acid was associated with a significantly higher
sensitivity versus gadopentetate dimeglumine (86.4%
versus 64.4%, respectively) for detecting small HCC
(0.5–2 cm) and a trend toward higher area under the
receiver operator characteristic curve (0.958 versus
0.927, respectively), which did not reach significance
(P ¼ 0.362) (80). Compared with MDCT, gadoxetic
acid-enhanced MRI appears to have similar sensitivity
and accuracy for larger HCC (>1.5 cm), but may show
an improvement over MDCT for smaller nodules
(48,49,81,82).
Consensus statement 4.1: The reported accuracy of
gadoxetic acid-enhanced MRI for diagnosis of HCC
compares favorably with that of MDCT and MRI per-
formed with extracellular agents (ECCM-MRI). Hence,
for the primary diagnosis of HCC, management guide-
lines should permit use of gadoxetic acid-enhanced
MRI as an alternative to multi-phasic CT or ECCM-
MRI (50/60 [83.3%] agreement).
A recent article highlighted that noninvasive imag-
ing strategies for 1–3 cm nodules, based on the EASL
and AASLD guidelines, required a second imaging
modality in 50% of cases, and that at least 10% of
HCC are missed completely (83). Additionally, it has
been reported that only 61% of HCC nodules show
hypervascularity according to the EASL criteria (44%
of 1–2 cm nodules), with 20% of nodules being hypo-
vascular in two imaging techniques (84). Therefore, it
is hypovascular HCCs that present a particular diag-
nostic challenge.
As discussed in section 3, HBP imaging in gadoxetic
acid-enhanced MRI aids the identification of hypovas-
cular premalignant and malignant lesions in the cir-
rhotic liver, due to the added information gained in
this phase. Early HCC and high-grade DN, which
largely appear hypointense to the parenchyma in this
phase, can be distinguished from low-grade DN and
RN, which tend to be iso- or hyperintense. Compared
with just the dynamic phase images, addition of the
HBP data in a study of gadoxetic acid-enhanced MRI
increased the sensitivity to identify and characterize
small hypovascular HCC (2 cm) from 88.4% to
99.4%, and also improved the specificity, accuracy,
and positive and negative predictive values (88% to
95%; 88% to 98.5%; 97% to 99%; and 65% to 97.5%,
respectively) (47). Furthermore, 19/20 atypical nodules
(those not showing arterial hypervascularity and portal
venous/delayed phase “washout”) were characterized
only during the HBP (47). Therefore, if a lesion can be
detected on gadoxetic acid-enhanced MR images (ie, if
it does not appear isointense), it can be more accu-
rately characterized. This suggests that if gadoxetic
acid-enhanced MRI is chosen as the initial imaging
modality for further investigation of suspected HCC, a
second modality may be less frequently required.
Consensus statement 4.2: With regard to indetermi-
nate, iso-/hypovascular nodules >1 cm identified
with MDCT or dynamic CE-MRI:
• Current evidence supports the incorporation into
management guidelines of hepatobiliary imaging
with gadoxetic acid-enhanced MRI for possible fur-
ther evaluation of such nodules (43/54 [79.6%]
agreement).
The current BCLC algorithm for early- and very
early-stage HCC recommends the size and number of
tumors as parameters to consider when reaching a
treatment decision (85). A retrospective analysis of
liver transplant patients has shown a linear relation-
ship between size of the largest HCC and tumor
recurrence, but a weaker association between the
number of tumors and recurrence (86), suggesting
that accuracy in measuring tumor diameter is the
more important consideration. There are no data
available showing that gadoxetic acid-enhanced MRI
provides more accurate measurement of tumor size
or number than either CT or ECCM-MRI. Treatment
decisions for advanced stage HCC according to the
BCLC algorithm should involve evaluation of vascular
6th International Liver MRI Forum Report 523
invasion and extra-hepatic spread (85); again, there
is no evidence in the literature that gadoxetic acid-
enhanced MRI provides better evaluation of vascular
invasion than other imaging modalities. Therefore,
with respect to reaching a treatment decision on
HCC, further evidence is required to recommend
inclusion of gadoxetic acid-enhanced MRI into the
guidelines.
With regard to treatment response, the modified
Response Evaluation Criteria in Solid Tumors (mRE-
CIST) specify that complete response should be based
on disappearance of tumoral enhancement in all tar-
get lesions (87). Hwang et al demonstrated that for
evaluation of the posttreatment viability of HCC,
gadoxetic acid-enhanced MRI showed higher diagnos-
tic accuracy than MDCT (96.3% versus 80.9–82.7%,
respectively) and better sensitivity (92.9–96.4% versus
53.6%, respectively) (88). The negative predictive
value was also higher for gadoxetic acid-enhanced
MRI (96.3–98.1% versus 79.5–80.0% for MDCT) (88).
However, we are not aware of any studies comparing
gadoxetic acid-enhanced MRI and ECCM-MRI to
assess treatment response, and to consider recom-
mending the inclusion of gadoxetic acid-enhanced
MRI into treatment-response guidelines, further data
are necessary.
As discussed previously, the finding of hypointensity
in the HBP of gadoxetic acid-enhanced MRI increases
diagnostic confidence for premalignant or malignant
lesions; however, to recommend inclusion of gadoxetic
acid-enhanced MRI in HCC management guidelines, it
must be shown that HCC can be adequately differenti-
ated from other non-HCC malignancy, such as CCC,
using this modality. Mass-forming intrahepatic CCCs
frequently appear as noncapsulated, lobulated
tumors, enabling differentiation from the round shape
of classic HCCs (89). However, as HCC may also have
a lobulated appearance, further gadoxetic acid-
enhanced MRI features should be considered. Mass-
forming CCCs typically show peripheral enhancement
in the early arterial phase, and progressive concentric
(centripetal) enhancement in the portal and delayed
phases, although atypical hypervascular mass-
forming CCCs with complete or partial arterial
enhancement and portal/delayed phase “washout”
occur in up to 47% of cases (90). The differentiation of
mass-forming intrahepatic CCC from hypovascular
HCC may be difficult. A recent study suggests that sig-
nal intensity on T2-weighted images may help in the
differentiation; in univariate analyses, the authors
found that the presence of hypo- or hyperintense areas
favors a diagnosis of CCC, while the presence of linear
hyperintensity or multifocal, tiny hyperintense foci
favors hypovascular HCC (89). In a multivariate analy-
sis, however, the authors found that the only inde-
pendent imaging feature on gadoxetic acid-enhanced
MRI that differentiates mass-forming CCCs from hypo-
vascular HCC was a central enhancing region with a
peripheral hypointense rim (a so-called “target”
appearance) on 10-minute HBP images (89), attribut-
able to intratumoral fibrous tissue. However, caution
is required in application of these findings, because
scirrhous HCCs (which have abundant fibrous stroma)
can show near identical imaging features to mass-
forming CCCs (89). One imaging feature that may
favor the diagnosis of scirrhous HCC is the presence
of strong, thick peripheral arterial enhancement (89),
although confirmatory studies are needed.
Consensus statement 4.3: For management guide-
lines to recommend gadoxetic acid-enhanced MRI as
the primary technique for diagnosis of HCC, prospec-
tively designed studies are needed to show the superi-
ority of gadoxetic acid-enhanced MRI over MDCT and
ECCM-MRI in per-lesion accuracy for the diagnosis of
HCC AND noninferiority for both of the following addi-
tional performance characteristics: (i) Per-patient
accuracy for staging, including determination of size
and number of HCCs, as well as presence of macro-
vascular invasion; (ii) Per-lesion specificity/PPV in dif-
ferentiating HCC from non-HCC malignancy such as
CCC (46/54 [85.2%] agreement).
Toward an Interpretation Guideline for Gadoxetic
Acid-Enhanced MRI in Patients at Risk for HCC
Regardless of the recommendation for gadoxetic acid-
enhanced MRI in HCC management guidelines, many
centers already use this imaging modality in their
routine clinical investigation of liver tumors. While
gadoxetic acid-enhanced MRI is used frequently, the
criteria applied for image assessment appear to vary
widely, and an interpretation guideline for this tech-
nique may be warranted.
A systematic literature search was carried out to
identify evidence for the predictive value of different
gadoxetic acid-enhanced MRI temporal enhancement
patterns in diagnosing hypervascular HCC in at-risk
patients. The “at-risk” population largely consists of
cirrhosis patients, but it also includes Asian chronic
hepatitis B patients without cirrhosis, as well as
patients with nonalcoholic fatty liver disease and
advanced fibrosis but without cirrhosis. The search
criteria were as follows, applied to studies published
between 1990 and 2012 in English and involving
humans: “(hepatocellular carcinoma OR hepatoma OR
HCC) AND (magnetic resonance imaging OR MRI OR
MR OR MR imaging OR NMRI) AND (eovist OR pri-
movist OR gadoxetic acid OR gadoxetate OR gadoxe-
tate disodium OR Gd-EOB OR Gd-EOB-DTPA OR
EOB-DTPA) NOT (metastasis OR metastases).” Thirty-
four studies were identified that contained either
explicit or extractable data on either (a) PPV for HCC
diagnosis or (b) presence of false positives (45–50,52–
54,76,77,80,81,89,91–110). The denominators for cal-
culating PPVs were not consistently supplied in these
manuscripts; however, the expert consensus of the
HCC management guidelines workgroup, and of the
entire forum, was considered in addition to the pub-
lished evidence. A challenge in performing the system-
atic review was the inconsistent terminology and
criteria used by different published studies; 19 of the
identified manuscripts applied 16 individual criteria
for diagnosing HCC on gadoxetic acid-enhanced MRI,
and 14 different sets of these criteria.
Four temporal enhancement patterns for hypervas-
cular lesions could be analyzed (Fig. 4). Most papers
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did not distinguish between the portal venous and
transitional phases; therefore, for the systematic
review, these phases were considered together.
A pattern consisting of arterial phase hyperen-
hancement with venous/transitional phase hypoen-
hancement had a reported or extracted PPV of 100%
for 1 cm HCC (46,47,50,54,80,91,93,95,108). Only
one published study reported a false positive finding
for lesions with this pattern (a 0.9 cm DN) (98). Most
studies considered HBP signal intensity as noncontri-
butory for establishing the diagnosis of HCC for nod-
ules or masses exhibiting this pattern. However, when
no “washout” is seen in the venous/transitional phase
(ie, the nodule appears isointense to the parenchyma),
the signal intensity in the HBP is an important factor
to help reach a diagnosis, as described below.
A lesion demonstrating arterial phase hyperenhance-
ment, venous/transitional phase isoenhancement and
HBP hypoenhancement in at-risk patients is most
likely to be HCC (48,77,81,93,100,102,103,105), but
the exact PPV could not be extracted from the selected
studies. However, based on published reports and the
experience of the liver forum participants, it is known
that, in at-risk patients, lesions with this temporal
enhancement pattern are not always HCC. Alternative
diagnoses for nodular lesions showing this enhance-
ment pattern are non-HCC malignancies such as intra-
hepatic CCCs, premalignant lesions like high-grade
DNs (96), nonmalignant lesions including hemangi-
omas (48,94) and DNs (98), and benign pseudolesions
such as arterioportal shunts (Fig. 4) (48,50,97,109). In
this circumstance, ancillary imaging features may be
useful. Ancillary features that, if present, may favor
the diagnosis of HCC include intralesional fat (105), a
capsule appearance (48), corona enhancement, and
mosaic architecture (47). Other ancillary features favor
malignant over benign entities, but are not specific for
HCC as these features may also occur in CCCs and
combined HCC-CCC tumors; these features include
mild-moderate T2 hyperintensity (45,54,80,93,101),
DWI hyperintensity and, if hemangioma is excluded
based on other features, lesional iron sparing. Con-
versely, size discrepancy between the arterial and HB
phases (97), and irregular shape (101), may favor the
diagnosis of a vascular pseudolesion. Despite these dif-
ferential diagnostic considerations, forum participants
from Japan indicated that some centers in Japan con-
sider a nodule with arterial hyperenhancement,
venous/transitional phase isoenhancement, and HBP
hypoenhancement on gadoxetic acid-enhanced MRI as
diagnostic for HCC in at-risk patients; this pattern is
also considered diagnostic of HCC in the 2010 updated
clinical practice guidelines endorsed by the JSH (10).
Consensus statement 4.4: In patients at risk for
HCC imaged with gadoxetic acid-enhanced MRI:
a) >1 cm arterial phase hyperenhancing nodules/
masses with portal venous phase/transitional
phase hypoenhancement are diagnostic for HCC
(50/57 [87.7%] agreement).
b) >1 cm arterial phase hyperenhancing nodules/
masses without portal venous phase/transitional
phase hypoenhancement but with HBP hypointen-
sity are highly suspicious, but not diagnostic, for
HCC (57/58 [98.3%] agreement).
(The term “diagnostic” is used here as a radiology
criterion, with the understanding that some degree of
uncertainty can never be completely eliminated).
Figure 4. Provisional interpretation guide for enhancement patterns in the imaging of hypervascular HCC using gadoxetic
acid-enhanced MRI. Schematic diagram illustrates, for lesions with arterial phase hyperenhancement, four different temporal
enhancement patterns at gadoxetic acid-enhanced MRI. Most published studies have not differentiated between the venous
and transitional phases; hence, these are considered together. For each pattern, a provisional interpretation based on pub-
lished evidence and expert opinion is suggested. Entities representing a differential diagnosis are listed. *Suggestive of HCC
with preserved OATP expression: focal uptake defects, heterogeneity, nodule-in-nodule appearance, absence of central scar,
hypointense rim. CCC, cholangiocellular carcinoma; DN, dysplastic nodule; FNH, focal nodular hyperplasia; HCC, hepatocel-
lular carcinoma; OATP, organic anion-transporting polypeptide; PPV, positive predictive value; RN, regenerative nodule.
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In at-risk patients, most lesions showing arterial
phase hyperenhancement, venous/transitional phase
isoenhancement and either HBP isoenhancement or
HBP hyperenhancement are benign. While some of
these lesions may represent HCC with preserved
OATP expression, the majority are likely to be RN,
DN, FNH-like lesions or pseudolesions (Fig. 4). The
PPVs for these enhancement patterns, however, are
currently unknown. Ancillary multiparametric fea-
tures may aid in the differential diagnosis of lesions
with these patterns. Because non-HCC malignancies
are not considered in the major differential diagnosis
for such lesions, any ancillary feature suggestive of
malignancy favors the diagnosis of HCC, including
features that in other circumstances may not be spe-
cific for HCC: mild-to-moderate T2 hyperintensity,
DWI hyperintensity, lesional iron sparing, intra-
lesional fat, a capsule appearance, and corona
enhancement. Additionally, for nodules demonstrating
HBP iso- or hyperintensity, HBP features that suggest
a diagnosis of HCC are focal defects in uptake (110),
heterogeneity (77,81,93,99), a nodule-in-nodule or
mosaic architecture (47), absence of a central scar
(110), presence of internal septation(s) (110), or a
hypointense rim (110).
SUMMARY
Gadoxetic acid-enhanced MRI shows potential for the
combined morphological and functional analysis of
the liver at the segmental level. This imaging modality
also provides accurate detection of metastatic liver
disease, with further improvements possible through
protocol optimizations. In the cirrhotic liver, gadoxetic
acid-enhanced MRI fosters diagnostic confidence for
the characterization and management of several nod-
ules, including “borderline” (arterial hypo-/isovascu-
lar HBP hypointense) lesions. Gadoxetic acid-
enhanced MRI performs favorably against CT and
ECCM-MRI for the diagnosis of HCC, but to be recom-
mended in HCC management guidelines as the pri-
mary diagnostic technique, more data are needed. An
interpretation guideline for the assessment of gadox-
etic acid-enhanced MRI images may be warranted to
improve standardization within and between centers.
ACKNOWLEDGMENTS
The Sixth International Forum for Liver MRI was sup-
ported by Bayer HealthCare, and all authors received
honoraria and travel expenses.
REFERENCES
1. Belghiti J, Hiramatsu K, Benoist S, Massault PP, Sauvanet A,
Farges O. Seven hundred forty-seven hepatectomies in the
1990s: an update to evaluate the actual risk of liver resection
(abstract). J Am Coll Surg 2000;191:38–46.
2. Jarnagin WR, Gonen M, Fong Y, et al. Improvement in periopera-
tive outcome after hepatic resection: analysis of 1,803 consecu-
tive cases over the past decade. Ann Surg 2002;236:397–406.
3. Karlo C, Reiner CS, Stolzmann P, et al. CT- and MRI-based volu-
metry of resected liver specimen: comparison to intraoperative
volume and weight measurements and calculation of conversion
factors (abstract). Eur J Radiol 2010;75:e107–e111.
4. Breitenstein S, Apestegui C, Petrowsky H, Clavien PA. “State of the
art” in liver resection and living donor liver transplantation: a world-
wide survey of 100 liver centers.World J Surg 2009;33:797–803.
5. Zorzi M, Barca A, Falcini F, et al. Screening for colorectal cancer
in Italy: 2005 survey. Epidemiol Prev 2007;31:49–60.
6. Guglielmi A, Ruzzenente A, Conci S, Valdegamberi A, Iacono C.
How much remnant is enough in liver resection? Dig Surg 2012;
29:6–17.
7. Seyama Y, Kokudo N. Assessment of liver function for safe
hepatic resection. Hepatol Res 2009;39:107–116.
8. Morris-Stiff G, Gomez D, Prasad R. Quantitative assessment of
hepatic function and its relevance to the liver surgeon. J Gastro-
intest Surg 2009;13:374–385.
9. European Association for the Study of the Liver,European
Organisation for Research and Treatment of Cancer. EASL-
EORTC Clinical Practice Guidelines: management of hepatocel-
lular carcinoma (abstract). J Hepatol 2012;56:908–943.
10. Kudo M, Izumi N, Kokudo N, et al. Management of hepatocellu-
lar carcinoma in Japan: consensus-based clinical practice
guidelines proposed by the Japan Society of Hepatology (JSH)
2010 updated version. Dig Dis 2011;29:339–364.
11. Makuuchi M, Kokudo N, Arii S, et al. Development of evidence-
based clinical guidelines for the diagnosis and treatment of
hepatocellular carcinoma in Japan. Hepatol Res 2008;38:37–51.
12. Abdalla EK, Denys A, Chevalier P, Nemr RA, Vauthey JN. Total
and segmental liver volume variations: implications for liver sur-
gery (abstract). Surgery 2004;135:404–410.
13. de Graaf W, van Lienden KP, Dinant S, et al. Assessment of
future remnant liver function using hepatobiliary scintigraphy
in patients undergoing major liver resection. J Gastrointest Surg
2010;14:369–378.
14. Bennink RJ, Tulchinsky M, de Graaf W, Kadry Z, van Gulik TM.
Liver function testing with nuclear medicine techniques is com-
ing of age (abstract). Semin Nucl Med 2012;42:124–137.
15. Bonekamp S, Kamel I, Solga S, Clark J. Can imaging modalities
diagnose and stage hepatic fibrosis and cirrhosis accurately?
(abstract). J Hepatol 2009;50:17–35.
16. Heye T, Yang SR, Bock M, et al. MR relaxometry of the liver: sig-
nificant elevation of T1 relaxation time in patients with liver cir-
rhosis. Eur Radiol 2012;22:1224–1232.
17. Tam HH, Collins DJ, Wallace T, Brown G, Riddell A, Koh DM. Seg-
mental liver hyperintensity in malignant biliary obstruction on dif-
fusion weighted MRI: associated MRI findings and relationship with
serum alanine aminotransferase levels. Br J Radiol 2012;85:22–28.
18. Van Beers BE, Pastor CM, Hussain HK. Primovist, eovist: what
to expect? (abstract). J Hepatol 2012;57:421–429.
19. Cho SH, Kang UR, Kim JD, Han YS, Choi DL. The value of
gadoxetate disodium-enhanced MR imaging for predicting post-
hepatectomy liver failure after major hepatic resection: a prelim-
inary study. Eur J Radiol 2011;80:e195–e200.
20. Katsube T, Okada M, Kumano S, et al. Estimation of liver func-
tion using T1 mapping on Gd-EOB-DTPA-enhanced magnetic
resonance imaging. Invest Radiol 2011;464:277–283.
21. Katsube T, Okada M, Kumano S, et al. Estimation of liver func-
tion using T2* mapping on gadolinium ethoxybenzyl diethylene-
triamine pentaacetic acid enhanced magnetic resonance
imaging. Eur J Radiol 2012;81:1460–1464.
22. Motosugi U, Ichikawa T, Oguri M, et al. Staging liver fibrosis by
using liver-enhancement ratio of gadoxetic acid-enhanced MR
imaging: comparison with aspartate aminotransferase-to-platelet
ratio index. Magn Reson Imaging 2011;29:1047–1052.
23. Tamada T, Ito K, Higaki A, et al. Gd-EOB-DTPA-enhanced MR
imaging: evaluation of hepatic enhancement effects in normal
and cirrhotic livers. Eur J Radiol 2011;80:e311–e316.
24. Yamada A, Hara T, Li F, et al. Quantitative evaluation of liver
function with use of gadoxetate disodium-enhanced MR imaging.
Radiology 2011;260:727–733.
25. Nilsson H, Nordell A, Vargas R, Douglas L, Jonas E, Blomqvist
L. Assessment of hepatic extraction fraction and input relative
blood flow using dynamic hepatocyte-specific contrast-enhanced
MRI. J Magn Reson Imaging 2009;29:1323–1331.
26. Nilsson H, Blomqvist L, Douglas L, Nordell A, Jonas E. Assess-
ment of liver function in primary biliary cirrhosis using Gd-
EOB-DTPA-enhanced liver MRI. HPB (Oxford) 2010;12:567–576.
526 Sirlin et al.
27. Sourbron S, Sommer WH, Reiser MF, Zech CJ. Combined quan-
tification of liver perfusion and function with dynamic gadoxetic
acid-enhanced MR imaging. Radiology 2012;263:874–883.
28. van den Broek MA, van Dam RM, Malago M, Dejong CH, van
Breukelen GJ, Olde Damink SW. Feasibility of randomized con-
trolled trials in liver surgery using surgery-related mortality or
morbidity as endpoint. Br J Surg 2009;96:1005–1014.
29. Wright M, Tidy C.Liver tumours. Patient.co.uk. Available at:
http://www.patient.co.uk/doctor/Liver-Tumours.htm. Accessed
October 16, 2012.
30. Semelka RC, Helmberger TK. Contrast agents for MR imaging of
the liver. Radiology 2001;218:27–38.
31. Nino-Murcia M, Olcott EW, Jeffrey RB Jr, Lamm RL, Beaulieu
CF, Jain KA. Focal liver lesions: pattern-based classification
scheme for enhancement at arterial phase CT. Radiology 2000;
215:746–751.
32. Semelka RC, Hussain SM, Marcos HB, Woosley JT. Perilesional
enhancement of hepatic metastases: correlation between MR
imaging and histopathologic findings-initial observations. Radi-
ology 2000;215:89–94.
33. Scurr ED, Collins DJ, Temple L, Karanjia N, Leach MO, Koh
DM. Appearances of colorectal hepatic metastases at diffusion-
weighted MRI compared with histopathology: initial observa-
tions. Br J Radiol 2012;85:225–230.
34. Kele PG, van der Jagt EJ. Diffusion weighted imaging in the
liver. World J Gastroenterol 2010;16:1567–1576.
35. Danet IM, Semelka RC, Leonardou P, et al. Spectrum of MRI
appearances of untreated metastases of the liver. AJR Am J
Roentgenol 2003;181:809–817.
36. Niekel MC, Bipat S, Stoker J. Diagnostic imaging of colorectal
liver metastases with CT, MR imaging, FDG PET, and/or FDG
PET/CT: a meta-analysis of prospective studies including
patients who have not previously undergone treatment. Radiol-
ogy 2010;257:674–684.
37. Jeong HT, Kim MJ, Park MS, et al. Detection of liver metastases
using gadoxetic-enhanced dynamic and 10- and 20-minute
delayed phase MR imaging. J Magn Reson Imaging 2012;35:
635–643.
38. Ichikawa T, Saito K, Yoshioka N, et al. Detection and characteri-
zation of focal liver lesions: a Japanese phase III, multicenter
comparison between gadoxetic acid disodium-enhanced mag-
netic resonance imaging and contrast-enhanced computed
tomography predominantly in patients with hepatocellular carci-
noma and chronic liver disease. Invest Radiol 2010;45:133–141.
39. Raman SS, Leary C, Bluemke DA, et al. Improved characteriza-
tion of focal liver lesions with liver-specific gadoxetic acid
disodium-enhanced magnetic resonance imaging: a multicenter
phase 3 clinical trial. J Comput Assist Tomogr 2010;34:163–172.
40. Kim YK, Park G, Kim CS, Yu HC, Han YM. Diagnostic efficacy of
gadoxetic acid-enhanced MRI for the detection and characterisa-
tion of liver metastases: comparison with multidetector-row CT.
Br J Radiol 2012;85:539–547.
41. Kim T, Murakami T, Takahashi S, Hori M, Tsuda K, Nakamura
H. Diffusion-weighted single-shot echoplanar MR imaging for
liver disease. AJR Am J Roentgenol 1999;173:393–398.
42. Koh DM, Collins DJ, Wallace T, Chau I, Riddell AM. Combining
diffusion-weighted MRI with Gd-EOB-DTPA-enhanced MRI
improves the detection of colorectal liver metastases. Br J Radiol
2012;85:980–989.
43. Nagle SK, Busse RF, Brau AC, et al. High resolution navigated
three-dimensional T(1) -weighted hepatobiliary MRI using gadox-
etic acid optimized for 1.5 tesla. J Magn Reson Imaging 2012;
36:890–899.
44. Bashir MR, Husarik DB, Ziemlewicz TJ, Gupta RT, Boll DT,
Merkle EM. Liver MRI in the hepatocyte phase with gadolinium-
EOB-DTPA: does increasing the flip angle improve conspicuity
and detection rate of hypointense lesions? J Magn Reson Imag-
ing 2012;35:611–616.
45. Ahn SS, Kim MJ, Lim JS, Hong HS, Chung YE, Choi JY. Added
value of gadoxetic acid-enhanced hepatobiliary phase MR imag-
ing in the diagnosis of hepatocellular carcinoma. Radiology
2010;255:459–466.
46. Di Martino M, Marin D, Guerrisi A, et al. Intraindividual com-
parison of gadoxetate disodium-enhanced MR imaging and 64-
section multidetector CT in the Detection of hepatocellular carci-
noma in patients with cirrhosis. Radiology 2010;256:806–816.
47. Golfieri R, Renzulli M, Lucidi V, Corcioni B, Trevisani F,
Bolondi L. Contribution of the hepatobiliary phase of Gd-EOB-
DTPA-enhanced MRI to Dynamic MRI in the detection of hypo-
vascular small (2 cm) HCC in cirrhosis. Eur Radiol 2011;21:
1233–1242.
48. Haradome H, Grazioli L, Tinti R, et al. Additional value of gadox-
etic acid-DTPA-enhanced hepatobiliary phase MR imaging in the
diagnosis of early-stage hepatocellular carcinoma: comparison
with dynamic triple-phase multidetector CT imaging. J Magn
Reson Imaging 2011;34:69–78.
49. Kim SH, Kim SH, Lee J, et al. Gadoxetic acid-enhanced MRI ver-
sus triple-phase MDCT for the preoperative detection of hepato-
cellular carcinoma. AJR Am J Roentgenol 2009;192:1675–1681.
50. Sun HY, Lee JM, Shin CI, et al. Gadoxetic acid-enhanced mag-
netic resonance imaging for differentiating small hepatocellular
carcinomas (2 cm in diameter) from arterial enhancing pseudo-
lesions: special emphasis on hepatobiliary phase imaging. Invest
Radiol 2010;45:96–103.
51. Motosugi U, Ichikawa T, Sou H, et al. Distinguishing hypervas-
cular pseudolesions of the liver from hypervascular hepatocellu-
lar carcinomas with gadoxetic acid-enhanced MR imaging.
Radiology 2010;256:151–158.
52. Kobayashi S, Matsui O, Gabata T, et al. Gadolinium ethoxyben-
zyl diethylenetriamine pentaacetic Acid-enhanced magnetic reso-
nance imaging findings of borderline lesions at high risk for
progression to hypervascular classic hepatocellular carcinoma.
J Comput Assist Tomogr 2011;35:181–186.
53. Kumada T, Toyoda H, Tada T, et al. Evolution of hypointense
hepatocellular nodules observed only in the hepatobiliary phase
of gadoxetate disodium-enhanced MRI. AJR Am J Roentgenol
2011;197:58–63.
54. Filippone A, Blakeborough A, Breuer J, et al. Enhancement of
liver parenchyma after injection of hepatocyte-specific MRI con-
trast media: a comparison of gadoxetic acid and gadobenate
dimeglumine. J Magn Reson Imaging 2010;31:356–364.
55. Motosugi U, Ichikawa T, Sano K, et al. Double-dose gadoxetic
Acid-enhanced magnetic resonance imaging in patients with
chronic liver disease. Invest Radiol 2011;46:141–145.
56. Higaki A, Tamada T, Sone T, et al. Potential clinical factors
affecting hepatobiliary enhancement at Gd-EOB-DTPA-enhanced
MR imaging. Magn Reson Imaging 2012;30:689–693.
57. Kanki A, Tamada T, Higaki A, et al. Hepatic parenchymal
enhancement at Gd-EOB-DTPA-enhanced MR imaging: correla-
tion with morphological grading of severity in cirrhosis and
chronic hepatitis. Magn Reson Imaging 2012;30:356–360.
58. Kubota K, Tamura T, Aoyama N, et al. Correlation of liver paren-
chymal gadolinium-ethoxybenzyl diethylenetriaminepentaacetic
acid enhancement and liver function in humans with hepatocel-
lular carcinoma. Oncol Lett 2012;3:990–994.
59. Nakamura S, Awai K, Utsunomiya D, et al. Chronological evalu-
ation of liver enhancement in patients with chronic liver disease
at Gd-EOB-DTPA-enhanced 3-T MR imaging: does liver function
correlate with enhancement? Jpn J Radiol 2012;30:25–33.
60. Motosugi U, Ichikawa T, Muhi A, et al. Magnetic resonance elas-
tography as a predictor of insufficient liver enhancement on
gadoxetic Acid-enhanced hepatocyte-phase magnetic resonance
imaging in patients with type C hepatitis and child-pugh class a
disease. Invest Radiol 2012;47:566–570.
61. Motosugi U, Ichikawa T, Sou H, et al. Liver parenchymal
enhancement of hepatocyte-phase images in Gd-EOB-DTPA-
enhanced MR imaging: which biological markers of the liver
function affect the enhancement? J Magn Reson Imaging 2009;
30:1042–1046.
62. Tajima T, Takao H, Akai H, et al. Relationship between liver
function and liver signal intensity in hepatobiliary phase of gad-
olinium ethoxybenzyl diethylenetriamine pentaacetic acid-
enhanced magnetic resonance imaging. J Comput Assist Tomogr
2010;34:362–366.
63. Gschwend S, Ebert W, Schultze-Mosgau M, Breuer J. Pharmaco-
kinetics and imaging properties of Gd-EOB-DTPA in patients with
hepatic and renal impairment. Invest Radiol 2011;46:556–566.
64. Kim HY, Choi JY, Park CH, et al. Clinical factors predictive of
insufficient liver enhancement on the hepatocyte-phase of Gd-
EOB-DTPA-enhanced magnetic resonance imaging in patients
with liver cirrhosis. J Gastroenterol [Epub ahead of print].
6th International Liver MRI Forum Report 527
65. Tschirch FT, Struwe A, Petrowsky H, Kakales I, Marincek B,
Weishaupt D. Contrast-enhanced MR cholangiography with Gd-
EOB-DTPA in patients with liver cirrhosis: visualization of the
biliary ducts in comparison with patients with normal liver
parenchyma. Eur Radiol 2008;18:1577–1586.
66. Tsuboyama T, Onishi H, Kim T, et al. Hepatocellular carcinoma:
hepatocyte-selective enhancement at gadoxetic acid-enhanced
MR imaging--correlation with expression of sinusoidal and cana-
licular transporters and bile accumulation. Radiology 2010;255:
824–833.
67. Tsuda N, Matsui O. Cirrhotic rat liver: reference to transporter
activity and morphologic changes in bile canaliculi--gadoxetic
acid-enhanced MR imaging. Radiology 2010;256:767–773.
68. Kim MJ, Rhee HJ, Jeong HT. Hyperintense lesions on gadoxetate
disodium-enhanced hepatobiliary phase imaging. AJR Am J
Roentgenol 2012;199:W575–W586.
69. Kobayashi S, Matsui O, Gabata T, et al. Relationship between
signal intensity on hepatobiliary phase of gadolinium ethoxyben-
zyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-
enhanced MR imaging and prognosis of borderline lesions of
hepatocellular carcinoma. Eur J Radiol 2012;81:3002–3009.
70. Sano K, Motosugi U, Ichikawa T, Morisaka H, Ichikawa S, Araki
T.The outcome of hypovascular nodules showing hyperintense
on hepatocyte-phase of gadoxetic acid-enhanced magnetic reso-
nance imaging: when does it become a conventional HCC? 4
years follow-up study. In: Proceedings of the Annual Meeting of
Radiological Society of North America, Chicago, November 25–
30, 2012.
71. Bartolozzi C, Battaglia V, Bargellini I, et al. Contrast-enhanced
magnetic resonance imaging of 102 nodules in cirrhosis: correla-
tion with histological findings on explanted livers. Abdominal
Imaging 2013;38:290–296.
72. Nakashima O, Sugihara S, Kage M, Kojiro M. Pathomorphologic
characteristics of small hepatocellular carcinoma: a special ref-
erence to small hepatocellular carcinoma with indistinct mar-
gins. Hepatology 1995;22:101–105.
73. Takayama T, Makuuchi M, Hirohashi S, et al. Early hepatocellu-
lar carcinoma as an entity with a high rate of surgical cure.
Hepatology 1998;28:1241–1246.
74. Kogita S, Imai Y, Okada M, et al. Gd-EOB-DTPA-enhanced mag-
netic resonance images of hepatocellular carcinoma: correlation
with histological grading and portal blood flow. Eur Radiol 2010;
20:2405–2413.
75. Sugitani S, Sakamoto M, Ichida T, Genda T, Asakura H,
Hirohashi S. Hyperplastic foci reflect the risk of multicentric
development of human hepatocellular carcinoma. J Hepatol
1998;28:1045–1053.
76. Motosugi U, Ichikawa T, Sano K, et al. Outcome of hypovascular
hepatic nodules revealing no gadoxetic acid uptake in patients
with chronic liver disease. J Magn Reson Imaging 2011;34:88–94.
77. Akai H, Matsuda I, Kiryu S, et al. Fate of hypointense lesions on
Gd-EOB-DTPA-enhanced magnetic resonance imaging. Eur J
Radiol 2012;81:2973–2977.
78. Takayama Y, Nishie A, Nakayama T, et al. Hypovascular hepatic
nodule showing hypointensity in the hepatobiliary phase of
gadoxetic acid-enhanced MRI in patients with chronic liver dis-
ease: prediction of malignant transformation. Eur J Radiol
2012;81:3072–3078.
79. Bruix J, Sherman M. Management of hepatocellular carcinoma:
an update. Hepatology 2011;53:1020–1022.
80. Park G, Kim YK, Kim CS, Yu HC, Hwang SB. Diagnostic efficacy
of gadoxetic acid-enhanced MRI in the detection of hepatocellu-
lar carcinomas: comparison with gadopentetate dimeglumine. Br
J Radiol 2010;83:1010–1016.
81. Akai H, Kiryu S, Matsuda I, et al. Detection of hepatocellular
carcinoma by Gd-EOB-DTPA-enhanced liver MRI: comparison
with triple phase 64 detector row helical CT. Eur J Radiol 2011;
80:310–315.
82. Inoue T, Kudo M, Komuta M, et al. Assessment of Gd-EOB-
DTPA-enhanced MRI for HCC and dysplastic nodules and com-
parison of detection sensitivity versus MDCT. J Gastroenterol
2012;47:1036–1047.
83. Leoni S, Piscaglia F, Golfieri R, et al. The impact of vascular and
nonvascular findings on the noninvasive diagnosis of small
hepatocellular carcinoma based on the EASL and AASLD crite-
ria. Am J Gastroenterol 2010;105:599–609.
84. Bolondi L, Gaiani S, Celli N, et al. Characterization of small nodules
in cirrhosis by assessment of vascularity: the problem of hypovas-
cularhepatocellular carcinoma.Hepatology 2005;42:27–34.
85. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet
2012;379:1245–1255.
86. Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after
liver transplantation in patients with hepatocellular carcinoma
beyond the Milan criteria: a retrospective, exploratory analysis.
Lancet Oncol 2009;10:35–43.
87. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment
for hepatocellular carcinoma. Semin Liver Dis 2010;30:52–60.
88. Hwang J, Kim SH, Kim YS, et al. Gadoxetic acid-enhanced MRI
versus multiphase multidetector row computed tomography for
evaluating the viable tumor of hepatocellular carcinomas treated
with image-guided tumor therapy. J Magn Reson Imaging 2010;
32:629–638.
89. Chong YS, Kim YK, Lee MW, et al. Differentiating mass-forming
intrahepatic cholangiocarcinoma from atypical hepatocellular
carcinoma using gadoxetic acid-enhanced MRI. Clin Radiol
2012;67:766–773.
90. Kim SH, Lee CH, Kim BH, et al. Typical and atypical imaging
findings of intrahepatic cholangiocarcinoma using gadolinium
ethoxybenzyl diethylenetriamine pentaacetic Acid-enhanced
magnetic resonance imaging. J Comput Assist Tomogr 2012;36:
704–709.
91. Kim YK, Kim CS, Han YM, Yu HC, Choi D. Detection of small
hepatocellular carcinoma: intraindividual comparison of gadox-
etic acid-enhanced MRI at 3.0 and 1.5 T. Invest Radiol 2011;46:
383–389.
92. Baek CK, Choi JY, Kim KA, et al. Hepatocellular carcinoma in
patients with chronic liver disease: a comparison of gadoxetic
acid-enhanced MRI and multiphasic MDCT. Clin Radiol 2012;
67:148–156.
93. Chou CT, Chen YL, Su WW, Wu HK, Chen RC. Characterization
of cirrhotic nodules with gadoxetic acid-enhanced magnetic
resonance imaging: the efficacy of hepatocyte-phase imaging.
J Magn Reson Imaging 2010;32:895–902.
94. Doo KW, Lee CH, Choi JW, Lee J, Kim KA, Park CM. “Pseudo
washout” sign in high-flow hepatic hemangioma on gadoxetic
acid contrast-enhanced MRI mimicking hypervascular tumor.
AJR Am J Roentgenol 2009;193:W490–W496.
95. Frericks BB, Loddenkemper C, Huppertz A, et al. Qualitative
and quantitative evaluation of hepatocellular carcinoma and cir-
rhotic liver enhancement using Gd-EOB-DTPA. AJR Am J Roent-
genol 2009;193:1053–1060.
96. Golfieri R, Grazioli L, Orlando E, et al. Which is the best MRI
marker of malignancy for atypical cirrhotic nodules: hypointen-
sity in hepatobiliary phase alone or combined with other fea-
tures? Classification after Gd-EOB-DTPA administration. J Magn
Reson Imaging 2012;36:648–657.
97. Goshima S, Kanematsu M, Watanabe H, et al. Gadoxetate
disodium-enhanced MR imaging: differentiation between early-
enhancing non-tumorous lesions and hypervascular hepatocel-
lular carcinomas. Eur J Radiol 2011;79:e108–e112.
98. Hwang J, Kim SH, Lee MW, Lee JY. Small (2 cm) hepatocellular
carcinoma in patients with chronic liver disease: comparison of
gadoxetic acid-enhanced 3.0 T MRI and multiphasic 64-
multirow detector CT. Br J Radiol 2012;85:e314–e322.
99. Jung G, Breuer J, Poll LW, et al. Imaging characteristics of
hepatocellular carcinoma using the hepatobiliary contrast agent
Gd-EOB-DTPA. Acta Radiol 2006;47:15–23.
100. Kim YK, Kim CS, Han YM, Park G. Detection of small hepatocel-
lular carcinoma: can gadoxetic acid-enhanced magnetic reso-
nance imaging replace combining gadopentetate dimeglumine-
enhanced and superparamagnetic iron oxide-enhanced mag-
netic resonance imaging? Invest Radiol 2010;45:740–746.
101. Kim YK, Kim CS, Han YM, Park G, Hwang SB, Yu HC. Compari-
son of gadoxetic acid-enhanced MRI and superparamagnetic
iron oxide-enhanced MRI for the detection of hepatocellular car-
cinoma. Clin Radiol 2010;65:358–365.
102. Lee S, Kim SH, Park CK, Kim YS, Lee WJ, Lim HK. Comparison
between areas with Gd-EOB-DTPA uptake and without in hepa-
tocellular carcinomas on Gd-EOB-DTPA-enhanced hepatobili-
ary-phase MR imaging: pathological correlation. J Magn Reson
Imaging 2010;32:719–725.
528 Sirlin et al.
103. Marin D, Di Martino M, Guerrisi A, et al. Hepatocellular carci-
noma in patients with cirrhosis: qualitative comparison of
gadobenate dimeglumine-enhanced MR imaging and multipha-
sic 64-section CT. Radiology 2009;251:85–95.
104. Mita K, Kim SR, Kudo M, et al. Diagnostic sensitivity of imaging
modalities for hepatocellular carcinoma smaller than 2 cm.
World J Gastroenterol 2010;16:4187–4192.
105. Onishi H, Kim T, Imai Y, et al. Hypervascular hepatocellular carci-
nomas: detection with gadoxetate disodium-enhanced MR imaging
andmultiphasicmultidetectorCT. Eur Radiol 2012;22:845–854.
106. Park Y, Kim SH, Kim SH, et al. Gadoxetic acid (Gd-EOB-DTPA)-
enhanced MRI versus gadobenate dimeglumine (Gd-BOPTA)-
enhanced MRI for preoperatively detecting hepatocellular carci-
noma: an initial experience. Korean J Radiol 2010;11:433–440.
107. Rhee H, Kim MJ, Park YN, Choi JS, Kim KS. Gadoxetic acid-
enhanced MRI findings of early hepatocellular carcinoma as
defined by new histologic criteria. J Magn Reson Imaging 2012;
35:393–398.
108. Sano K, Ichikawa T, Motosugi U, et al. Imaging study of early
hepatocellular carcinoma: usefulness of gadoxetic acid-
enhanced MR imaging. Radiology 2011;261:834–844.
109. Shinagawa Y, Sakamoto K, Fujimitsu R, et al. Pseudolesion of the
liver observed on gadoxetate disodium-enhanced magnetic reso-
nance imaging obtained shortly after transarterial chemoemboliza-
tion for hepatocellular carcinoma. Jpn J Radiol 2010;28:483–488.
110. Suh YJ, Kim MJ, Choi JY, Park YN, Park MS, Kim KW. Differen-
tiation of hepatic hyperintense lesions seen on gadoxetic acid-
enhanced hepatobiliary phase MRI. AJR Am J Roentgenol 2011;
197:W44–W52.
6th International Liver MRI Forum Report 529
